HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.1510
https://www.valueinhealthjournal.com/article/S1098-3015(23)04640-5/fulltext
Section Title :
Section Order :
10959
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04640-5&doi=10.1016/j.jval.2023.09.1510